Terfenadine ((±)-Terfenadine) 是一种有效的hERG开放通道抑制剂,IC50为 204 nM。Terfenadine 也是一种H1 组胺受体 (histamine receptor)拮抗剂,通过调节Ca2+稳态在黑素瘤细胞中起到有效的细胞凋亡诱导作用。 Terfenadine 诱导 ROS 依赖性细胞凋亡,同时激活Caspase-4,-2,-9。
生物活性 | Terfenadine ((±)-Terfenadine) is a potent open-channel blocker ofhERGwith anIC50of 204 nM[1]. Terfenadine, anH1histamine receptorantagonist, acts as a potentapoptosisinducer in melanoma cells through modulation ofCa2+homeostasis. Terfenadine induces ROS-dependentapoptosis, simultaneously activatesCaspase-4, -2, -9[2]. |
IC50& Target | H1Receptor | Caspase-4 | Caspase-2 | Caspase-9 |
|
体外研究 (In Vitro) | Terfenadine ((±)-Terfenadine) (4-20 μM; 24 hours) induces dose and time-dependent apoptosis on A375 melanoma cells. The IC50after 24 h of TEF treatment in complete medium was 10.4 μM for A375 cells, 9.9 μM for Hs294T cells and 9.6 for HT144 cells[2]. Terfenadine (2-10 μM; 8 hours) induces dose-dependent cytotoxicity[2]. Terfenadine (10 μM; 8 hours) causes a massive vacuolization of the cytoplasm and autophagic vacuoles of both double and multiple membranes and at various stages. Terfenadine induces autophagy by ROS-dependent and -independent mechanisms[2].
Apoptosis Analysis[2] Cell Line: | A375, HT144 and Hs294T cells | Concentration: | 4, 8, 12, 16, 20 μM | Incubation Time: | 24 hours | Result: | Induced dose and time-dependent apoptosis. |
Cell Cytotoxicity Assay[2] Cell Line: | A375 melanoma cells | Concentration: | 2, 4, 6, 8, 10 μM | Incubation Time: | 8 hours | Result: | Induces dose-dependent cytotoxicity. |
Cell Autophagy Assay[2] Cell Line: | A375 cells | Concentration: | 10 μM | Incubation Time: | 8 hours | Result: | Caused a massive vacuolization of the cytoplasm and autophagic vacuoles of both double and multiple membranes and at various stages. |
|
体内研究 (In Vivo) | Terfenadine (p.o.; 40 mg/kg; for 16 days) produces a significant inhibition of tumour growth rate and enhances the anti-cancer effect of EPI in chemo-resistant NSCLC xenograft models[3].
Animal Model: | 6-week-old male BALB/cA-nu mice[3] | Dosage: | 40 mg/kg | Administration: | P.o.; for 16 days | Result: | Produced a significant inhibition of tumour growth rate. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(106.01 mM) H2O : 0.67 mg/mL(1.42 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 2.1201 mL | 10.6006 mL | 21.2013 mL | 5 mM | 0.4240 mL | 2.1201 mL | 4.2403 mL | 10 mM | 0.2120 mL | 1.0601 mL | 2.1201 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.30 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.30 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (5.30 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|